Traws Pharma Inc TRAW

$0.57 +0.02 (4.25%)

Valuation

Market cap
8,380,000
Revenue TTM
$2,790,000
Net income TTM
$9,170,000
PE ratio
0.00
Forward PE
—
Profit margin
328.67%
Debt to equity
0.00

Trading

Volume
69,600
Avg volume
689,232
Day's range
$0.55 – $0.57
Shares out
15,368,000
Stochastic %K
40%
Beta
1.52
Analysts
Hold
Price target
$1.00

Price

Company profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in d...

Show more

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
267 759 3680
Website
https://www.trawspharma.com
Address
12 Penns Trail, Newtown, United States

Latest news

Stocktwits

tbone212371 Sep 28, 4:35 PM
$TRAW let's play
0 replies
UltraInstinctVegeta Sep 26, 11:12 PM
$YFOR $TRAW Why I believe everyone should be bullish on Solar. Solar is the future. Solar can be deployed quickly, scales massively, and continues getting cheaper. -FTCI one of the beaten down Solar gems, look below why it's so undervalued..
0 replies
416trader Sep 25, 8:21 PM
$TRAW they try to bring this down PM and AH. Brought it down to 0.46 last night. I dare you to do it again and I’ll just accumulate more. This one is a no brainer at these lows with catalyst coming any day.
0 replies
PrintingGains Sep 25, 7:17 PM
$TRAW Need a round 2, volume still high average
0 replies
CoffeeRocks Sep 25, 8:55 AM
$INO bio stocks kick off again with uncertainty in markets oil up oil down Crypto up crypto down $TRAW $AIM $GOVX Few plays here that will $CODX 5-10x
1 replies
TheTinyDevil Sep 24, 10:54 PM
$TRAW Oof... chart looked like it was trying to play again and then it just started melting.
0 replies
STOCKSGambino Sep 24, 8:58 PM
$TRAW https://x.com/StocksGambino/status/2103225482875478245
0 replies
416trader Sep 24, 8:40 PM
$TRAW Perceptive Advisors lead by Joseph Edelman does not fail. Biggest winner was $DRUG
0 replies